<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 38-year-old Japanese man with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), whose bone marrow smears demonstrated hypercellularity, was treated with oral <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CsA) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>During the course of this therapy, the numbers of peripheral blood and bone marrow blasts increased and the level of serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase increased </plain></SENT>
<SENT sid="2" pm="."><plain>After discontinuation of CsA treatment, <z:hpo ids='HP_0000001'>all</z:hpo> of these levels rapidly decreased </plain></SENT>
<SENT sid="3" pm="."><plain>We consider that CsA might accelerate disease progression in certain <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
</text></document>